BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 9, Issue 18
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4491-4499
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4491
Table 2 Drug-drug interaction between antiretroviral drugs and direct-acting antiviral agents
Antiretroviral drugs
SOF/LED
SOF/VEL
SOF/VEL/VOX
EBR/GZR
GLE/PIB
NRTIs
Tenoforvir disoproxil fumarate▲▲▲--
NNRTIs
Efavarenz-XXXX
Etravirenz-XXXX
Nevirapine-XXXX
Protease inhibitors
Atazanavir/ritonavir--XXX
Atazanavir/cobicistat --XXX
Darunavir/ritonavir--XXX
Darunavir/cobicistat---XX
Lopinavir/ritonavir--XXX
▲: Should be avoided in patients with an eGFR < 60 mL/min; X: Should be avoided; EBR: Elbasvir; GLE: Glecaprevir; GZR: Grazoprevir; LDV: Ledipasvir; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PIB: Pibrentasvir; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.